Inflectra® /CT-P13* (infliximab) has comparable efficacy to Remicade®† in AS19,21,36.

ASAS20 response in adult patients with active AS19,21,36

Planetas Efficacy Results

  • All efficacy endpoints were comparable during long-term treatment in the maintenance and switch groups21 

 

Inflectra® / CTP13* (infliximab) safety profile was maintained long term in AS19,21,36.

Treatment-emergent adverse events (TEAE)19,21,36

Planetas Safety Results

 

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.

AS, Ankylosing spondyloarthritis; ASAS, Assessment of Spondyloarthritis International Society; CI, Confidence interval; OR, Odds ratio.

 

PP-IFA-GBR-0290. December 2018